To include your compound in the COVID-19 Resource Center, submit it here.

Celgene reports detailed Phase III data for MS candidate ozanimod

Celgene Corp. (NASDAQ:CELG) reported detailed data from the double-blind, international Phase III SUNBEAM and RADIANCE trials of oral ozanimod (RPC1063) to treat relapsing multiple sclerosis.

Ozanimod is the next closest launch in Celgene’s pipeline after the company discontinued development of Phase III Crohn’s disease candidate mongersen (GED-0301) following an interim futility analysis. Mongersen, an antisense oligonucleotide targeting SMAD family member 7 (SMAD7; MADH7), had been expected

Read the full 651 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE